Envoy Medical Inc.
COCH evidence brief
What we can confirm
- BioSniper Score:
- 3.4 / 10
- Market Cap:
- $55.1M
- Lead Asset:
- acclaim ci (Preclinical)
What it means
What to watch
Prepared research question
What matters most for COCH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · COCH
Envoy Medical Inc. (COCH) is a hearing health company developing a fully implanted cochlear implant, the Acclaim CI, which is currently in a pivotal FDA clinical trial and has not yet been approved for sale.
Key risk: Cash runway risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$55.1M
Cash Runway
—
Lead Asset
acclaim ci (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Envoy Medical Inc..
Envoy Medical Inc. (COCH) is a hearing health company developing a fully implanted cochlear implant, the Acclaim CI, which is currently in a pivotal FDA clinical trial and has not yet been approved for sale.
- Envoy Medical is focused on developing fully implanted hearing solutions, with its lead product candidate being the Acclaim CI [sec_mda · as of 2026-05-11].
- As of June 30, 2026, the company reported total revenue of $0.1M and a net loss of -$6.0M [sec].
- Cash and cash equivalents were $19,679 as of June 30, 2026, up from $3,739 at December 31, 2025 [sec_mda · as of 2026-08-10].
- The Acclaim CI has not yet been approved for sale, and the company does not expect product sales unless and until regulatory approval is obtained [sec_mda · as of 2026-08-10].
- In July 2026, the company announced that all 56 patients in the pivotal clinical trial had surpassed the three-month milestone [news · published 2026-07-21].
What works
- The FDA approved advancement of the pivotal clinical trial to the second and final stage based on three-month data from the first 10 participants, with no serious adverse events reported [sec_mda · as of 2025-11-10].
- All 56 patients enrolled in the pivotal trial have passed the three-month milestone, indicating continued clinical progress [news · published 2026-07-21].
- The company has demonstrated ability to raise capital through equity offerings, such as the October 2025 registered direct offering and private placement [sec · filed 2026-02-06].
What to weigh
- The company has incurred significant operating losses since inception and expects to continue doing so for the foreseeable future [sec_mda · as of 2026-08-10].
- As of June 30, 2026, cash on hand was only $19,679, which is extremely low relative to ongoing expenses [sec_mda · as of 2026-08-10].
- The Acclaim CI has not yet been approved for sale, and the company may never generate product revenue if development or regulatory approval fails [sec_mda · as of 2026-08-10].
- Financial performance is expected to fluctuate significantly due to the development status of the Acclaim CI and efforts to obtain regulatory approval [sec_mda · as of 2026-08-10].
From the filings
Quoted directly from source documents.
The company's cash position as of June 30, 2026
“As of June 30, 2026 and December 31, 2025 we had $19,679 and $3,739 of cash, respectively.”
SEC MD&A · August 10, 2026
The Acclaim CI has not yet been approved for sale
“The Acclaim CI has not yet been approved for sale.”
SEC MD&A · August 10, 2026
All 56 patients in the pivotal trial have passed the three-month milestone
“surpassed the three-month milestone for all 56 patients enrolled in the company’s pivotal clinical trial”
News · July 21, 2026
The company has incurred significant operating losses since inception
“Since inception, we have incurred significant operating losses.”
SEC MD&A · August 10, 2026
Risks & what to watch (4)›
Key risks
- Cash runway risk — Cash of only $19,679 as of June 30, 2026 is extremely low, threatening ability to fund operations [sec_mda · as of 2026-08-10].
- No product revenue yet — Acclaim CI not approved for sale; no product revenue expected unless regulatory approval is obtained [sec_mda · as of 2026-08-10].
- Clinical trial uncertainty — Pivotal trial results may fail to demonstrate safety or efficacy, preventing FDA approval [sec_mda · as of 2026-08-10].
- Dependence on external financing — Company relies on equity and debt offerings to fund operations; future financing may not be available [sec_mda · as of 2026-08-10].
What to watch
- Completion of the pivotal clinical trial for the Acclaim CI and submission of FDA marketing application [news · published 2026-07-21].
- Changes in cash position and ability to raise additional capital through equity or debt offerings [sec_mda · as of 2026-08-10].
- Any FDA decisions or regulatory milestones regarding the Acclaim CI [sec_mda · as of 2026-08-10].
- Financial results for subsequent quarters, particularly revenue and net loss figures [sec].
Sources: News · SEC filings · SEC MD&A · Generated October 11, 2026 · How we verify sources →
Run Envoy Medical Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Envoy Medical Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 6.13 · 0% dilution
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Short Interest
as of May 20, 2026- % of float
- 3.0%
- Days to cover
- 8.8
- Shares short
- 1,357,337
- Daily short volume (Apr 30, 2026)
- 32.5%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
COCH short interestGovernance
Frequently asked questions
What is the AI investment thesis for Envoy Medical Inc.?
Envoy Medical Inc. (COCH) is a hearing health company developing a fully implanted cochlear implant, the Acclaim CI, which is currently in a pivotal FDA clinical trial and has not yet been approved for sale.
What is Envoy Medical Inc.'s lead drug candidate?
Envoy Medical Inc.'s most advanced tracked candidate is acclaim ci (Preclinical) for Severe-to-profound sensorineural hearing loss.
Who is the CEO of Envoy Medical Inc.?
Mr. Brent T. Lucas Esq. is the chief executive officer of Envoy Medical Inc. (COCH).
Where is Envoy Medical Inc. headquartered?
Envoy Medical Inc. (COCH) is headquartered in White Bear Lake, MN, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.